612 related articles for article (PubMed ID: 33752741)
1. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.
Tan DHS; Chan AK; Jüni P; Tomlinson G; Daneman N; Walmsley S; Muller M; Fowler R; Murthy S; Press N; Cooper C; Lee T; Mazzulli T; McGeer A
Trials; 2021 Mar; 22(1):224. PubMed ID: 33752741
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.
Smit M; Marinosci A; Nicoletti GJ; Perneger T; Ragozzino S; Andrey DO; Stoeckle M; Jacquerioz F; Lebowitz D; Agoritsas T; Meyer B; Spechbach H; Salamun J; Back M; Schaubhut C; Fuchs S; Decosterd L; Battegay M; Guessous I; Chappuis F; Kaiser L; Labhardt ND; Calmy A
BMJ Open; 2020 Nov; 10(11):e040110. PubMed ID: 33184083
[TBL] [Abstract][Full Text] [Related]
3. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial.
Labhardt ND; Smit M; Petignat I; Perneger T; Marinosci A; Ustero P; Diniz Ribeiro MP; Ragozzino S; Nicoletti GJ; Faré PB; Andrey DO; Jacquerioz F; Lebowitz D; Agoritsas T; Meyer B; Spechbach H; Salamun J; Guessous I; Chappuis F; Kaiser L; Decosterd LA; Grinsztejn B; Bernasconi E; Cardoso SW; Calmy A; Team FTCS
EClinicalMedicine; 2021 Dec; 42():101188. PubMed ID: 34778734
[TBL] [Abstract][Full Text] [Related]
4. Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.
Manoharan L; Olliaro P; Horby PW; Watson CH
Trials; 2021 May; 22(1):370. PubMed ID: 34051840
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial.
Kaizer AM; Shapiro NI; Wild J; Brown SM; Cwik BJ; Hart KW; Jones AE; Pulia MS; Self WH; Smith C; Smith SA; Ng PC; Thompson BT; Rice TW; Lindsell CJ; Ginde AA
Int J Infect Dis; 2023 Mar; 128():223-229. PubMed ID: 36581186
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
8. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
[TBL] [Abstract][Full Text] [Related]
9. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
Lother SA; Abassi M; Agostinis A; Bangdiwala AS; Cheng MP; Drobot G; Engen N; Hullsiek KH; Kelly LE; Lee TC; Lofgren SM; MacKenzie LJ; Marten N; McDonald EG; Okafor EC; Pastick KA; Pullen MF; Rajasingham R; Schwartz I; Skipper CP; Turgeon AF; Zarychanski R; Boulware DR
Can J Anaesth; 2020 Sep; 67(9):1201-1211. PubMed ID: 32383125
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
11. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
Arabi YM; Alothman A; Balkhy HH; Al-Dawood A; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Assiri AM; Al-Hameed F; AlSaedi A; Mandourah Y; Almekhlafi GA; Sherbeeni NM; Elzein FE; Memon J; Taha Y; Almotairi A; Maghrabi KA; Qushmaq I; Al Bshabshe A; Kharaba A; Shalhoub S; Jose J; Fowler RA; Hayden FG; Hussein MA;
Trials; 2018 Jan; 19(1):81. PubMed ID: 29382391
[TBL] [Abstract][Full Text] [Related]
13. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
[No Abstract] [Full Text] [Related]
16. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
[TBL] [Abstract][Full Text] [Related]
17. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
19. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
Singh A
Ann Intern Med; 2021 Jan; 174(1):JC3. PubMed ID: 33395331
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.
Ford N; Vitoria M; Rangaraj A; Norris SL; Calmy A; Doherty M
J Int AIDS Soc; 2020 Apr; 23(4):e25489. PubMed ID: 32293807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
